The global fiducial markers market was valued at USD 102.2 million in 2019. Market growth is expected to increase to the increasing incidence of various cancers, such as breast, lung, and prostate cancer, and to the growing use of radiotherapy for oncology therapies. It is expected that the understanding of selective radiotherapy strategies such as image-guided radiotherapy, intensity-modulated radiotherapy, and stereotactic radiosurgery would lead to the adoption of fiduciary markers. Because of the chemotherapy-related risks and side effects and selective drug therapy, radiotherapy choice is expected to see a steep increase over the projected period.
In order to obtain an effective dosage of radiation, fiducial markers are inserted in or around a tumour during the radiotherapy process to identify the tumour. To build an innovative navigation device for proper positioning of the product, there have been many technical developments. For example, Veran Medical Technologies' advanced navigation technology of the SPiN Device helps identify the target to position the fiducial marker correctly for radiation or resection. A 3D view of fiducials is also provided by this technology and the report is created for proper diagnosis and care.
However, its acceptance may be affected by problems associated with product implantation and use. Patients who have undergone transrectal fiducial marker injection for image-guided treatment for prostate cancer contracted from haematuria, rectal bleeding from haematospermia, and dysuria as per NCBI.
Fiducial Markers Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 150.4 million|
|Growth Rate||CAGR of 4.0% during 2021-2028|
|Segment Covered||Product, Modality, Application, End User, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Key Players Profiled||QlRad, Inc., QFIX, Boston Scientific Corp., CIVCO Radiotherapy, IZI Medical Products, Naslund Medical AB, Medtronic PLC, Nanovi A/S, Eckert & Ziegler, IBA Dosimetry GmbH, and many more among others.|
Key segments of the global fiducial markers market
Product Overview, 2018-2028 (USD Million)
- Gold Combination
- Other Metal
Modality Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
- Breast cancer
- Lung cancer
- Prostate cancer
- Head and neck cancer
End User Overview, 2018-2028 (USD Million)
- Radiotherapy center
- Academic and research center
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
Reasons for the study
- Increasing Government Support for the Pharmaceutical & Biotechnology Industry
- Growth in Biopharmaceutical Industry
What does the report include?
- The study on the global fiducial markers market includes analysis of qualitative market indicators such as drivers, restraints, challenges and opportunities
- Additionally, the market competition has been evaluated using the Porter’s five forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of product, modality, end user, application. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the considered segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global fiducial markers market is suitable for all the players across the value chain including raw material suppliers, fiducial markers providers, pharmaceutical and medical device manufacturers, distributors, suppliers and retailers
- Venture capitalists and investors looking for more information on the future outlook of the global fiducial markers market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global fiducial markers market
Fiducial marker positioning requires ultrasound instructions in preparation for radiation treatment to insert small metal artefacts called fiducial markers in or around a tumour. The markers help more precisely define the site of the tumour and allow the treatment team to administer the full dose of radiation to the tumour while sparing healthy tissue.
In all imaging techniques of concern with the least modification of visual acuity (artefacts), an optimal fiducial marker should be evident. It is particularly important to reduce the effects of artefacts on the planning of CT scans, as artefacts can interfere with the precision of structure delineation and dose measurement. A variety of experimental findings of dose disruptions from gold fiduciary markers have been published. Predominantly, gold fiducial markers are used and various sizes and shapes from different suppliers are available. However, there are now available commercially markers on the market with diverse materials, sizes.
The global market is segmented based on product, end user and application. The product segment is further broken down to gold, gold combination, polymer, other metal, liquid. In terms of application, the market is bifurcated into breast cancer, lung cancer, prostate cancer, head and neck cancer, and others. Based on modality, the market is segmented into CT/CBCT, MRI, ultrasound, and X-Ray.
Owing to the accurate illumination and superior stability of these items across many imaging modalities, the gold category held the largest share in 2019. For improved performance, gold fiducial markers often come in conjunction with other metals, such as titanium, platinum, and nickel. For example, these markers improve the clarity in MRI images when paired with titanium stripes.
In order to design goods with better performance, big corporations are spending more in R&D. IBA Dosimetry GmbH, introduced a linear pure gold fiducial marker called Visicoil, a special hollow core helical shaped substance that reduces the occurrence of typical complications such as migration of markers and objects. It is also predicted that the polymer segment will register substantial growth over the forecast period. It is anticipated that the lower cost of these items than that of other metal markers would lead to segment growth. On the other hand, over the projected period, liquid fiduciary markers are predicted to undergo the highest CAGR.
On the basis of region, the global market is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East and Africa. In 2019, North America dominated the global market and is antipcated to maintain its leading position through 2028. Primary factors anticipated to fuel development in the region are the strong participation of major industry players, simplified payment schemes, and public health initiatives. In addition, the growing acceptance of advanced radiotherapy procedures and imaging modalities would improve the region's product demand, fostering business growth.
Key players in the market include QlRad, Inc., QFIX, Boston Scientific Corp., CIVCO Radiotherapy, IZI Medical Products, Naslund Medical AB, Medtronic PLC, Nanovi A/S, Eckert & Ziegler, IBA Dosimetry GmbH, and many more among others.